Translational research
57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

https://doi.org/10.1016/S1556-0864(16)30171-XGet rights and content
Under an Elsevier user license
open archive

Cited by (0)

Copyright © 2016 European Lung Cancer Conference organisers, ESMO and IASLC. Published by Elsevier Inc. All rights reserved.